VFValeria Fiaccadori

Valeria Fiaccadori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valeria Fiaccadori has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of a novel homozygous CTLA4 variant

    by Tegan McTaggart, Jing Xuan Lim, Arda Akchengel, Katie Smith, Sophia Landell-Wright, Austen Worth, Valeria Fiaccadori, Ian Proctor, Shoba Amarnath, Ben Carpenter, et al.

    Cytotoxic T lymphocyte–associated antigen-4 (CTLA4) is an inhibitory co-receptor. We report a homozygous variant in CTLA4 residing in the 3′UTR of the CTLA4 gene. The patient was deficient in peripheral blood T regulatory cells that was partially reversed with abatacept.

  • Paediatric thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency and organomegaly syndrome: The United Kingdom experience

    by Luisa Cortellazzo Wiel, Ahmed Zeidan, Nikki Pelech, Samantha Jayne Williamson, Kirsty Haslam, Mark Wood, Valeria Fiaccadori, Ben Carpenter, Jeanette Payne, Biju Charles, et al.

  • Relapse patterns in early‐PET negative, limited‐stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy–a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials

    by Valeria Fiaccadori, Anouk Neven, Catherine Fortpied, Igor Aurer, Marc Andre, Massimo Federico, Nicholas Counsell, Elizabeth H. Phillips, Laura Clifton‐Hadley, Sally F. Barrington, et al.

    Summary: In the H10 and RAPID randomised trials, chemotherapy+radiotherapy (combined modalities treatment, CMT) was compared with chemotherapy (C) in limited‐stage Hodgkin lymphoma (HL), with negative early positron emission tomography (ePETneg). We analysed patterns of relapses in the H10 trial, validated findings in the RAPID trial and performed a combined analysis stratified by trial. The impact of radiotherapy (RT) on risk of relapse was studied using adjusted Cox models, with time‐varying effects. In H10, 1,059 ePETneg patients were included (465 European Organisation for Research and Treatment of Cancer (EORTC) favourable [F], 594 unfavourable [U]). Among the F patients, 2/227 (1%) relapsed after CMT, 30/238 (13%) after C: of these relapses, 21/30 (70%) occurred in less than 2 years and 25/30 (83%) affected originally involved areas. Among the U group, 16/292 (5%) relapsed after CMT: 8/16 (50%) in less than 2 years, 11/16 (69%) in originally involved areas. After C 30/302 (10%) relapsed: 27/30 (90%) in less than 2 years, and 26/30 (87%) in originally involved areas. Similar results were observed in 419 ePETneg RAPID patients (241 F, 128 U, 50 unclassified): among F patients, 6/118 (5%) relapsed after CMT; 13/123 (11%) after C: 11/13 (85%) in less than 2 years and 11/13 (85%) affecting originally involved areas. In U patients, 3/65 (5%) relapsed after CMT and 5/63 (8%) after C. In both trials, omitting RT in ePETneg HL resulted in more early relapses, mainly affecting originally involved areas. RT significantly reduced risk of early relapses in the combined stratified analysis.


  • Open Access

    Therapy-Related Late Adverse Events in Hodgkin’s Lymphoma

    by Manuel Gotti, Valeria Fiaccadori, Elisa Bono, Benedetta Landini, Marzia Varettoni, Luca Arcaini, Maurizio Bonfichi

    Hodgkin's lymphoma (HL) is one of the most curable hematologic diseases with an overall response rate over 80%. However, despite this therapeutic efficacy, HL survivors show a higher morbidity and mortality than other people of the same age because of long-term therapy-related events. In the last decades, many efforts have been made to reduce these effects through the reduction of chemotherapy dose, the use of less toxic chemotherapeutic agents, and the introduction of new radiation techniques. In this paper, we will describe the main long-term effects related to chemotherapy and radiotherapy for HL, the efforts to reduce toxicity made in the last years, and the clinical aspects which have to be taken into consideration in the followup of these patients.